847361-96-0

Basic information

• Product Name: MacaMide IMpurity 5
• Synonyms: MacaMide IMpurity 5;N-(3-Methoxybenzyl)palmitamide;N-(3-methoxybenzyl)-hexadecanamide
• CAS NO: 847361-96-0
• Molecular Formula: C24H41NO2
• Molecular Weight: 375.59
• Mol File: 847361-96-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 532.1±33.0 °C(Predicted)
• Appearance: /
• Density: 0.939±0.06 g/cm3(Predicted)
• PKA: 15.78±0.46(Predicted)
• CAS DataBase Reference: MacaMide IMpurity 5(CAS DataBase Reference)
• NIST Chemistry Reference: MacaMide IMpurity 5(847361-96-0)
• EPA Substance Registry System: MacaMide IMpurity 5(847361-96-0)

Safety Data

• Hazardous Substances Data: 847361-96-0(Hazardous Substances Data)

Usage

General Description

MacaMide Impurity 5 is a chemical compound that is classified as an impurity in macamide, which is a bioactive compound found in the plant maca, also known as Lepidium meyenii. Macamide impurity 5 is a by-product formed during the production process of macamide and is known to have potential effects on the endocannabinoid system in the body. It is considered an impurity because it is not the primary desired compound, but it may still have biological activity and therefore must be closely monitored and controlled during the production of macamide. Further research is likely necessary to fully understand the properties and potential effects of Macamide Impurity 5.

Upstream product

• 5071-96-5 3-METHOXYBENZYLAMINE 
• 57-10-3 1-hexadecylcarboxylic acid 

Relevant articles and documents

N-Benzyl-linoleamide, a Constituent of Lepidium meyenii (Maca), Is an Orally Bioavailable Soluble Epoxide Hydrolase Inhibitor That Alleviates Inflammatory Pain

Lepidium meyenii (maca), a plant indigenous to the Peruvian Andes, recently has been utilized globally for claimed health or recreational benefits. The search for natural products that inhibit soluble epoxide hydrolase (sEH), with therapeutically relevant potencies and concentrations, led to the present study on bioactive amide secondary metabolites found in L. meyenii, the macamides. Based on known and suspected macamides, 19 possible macamides were synthesized and characterized. The majority of these amides displayed excellent inhibitory potency (IC50 ≈ 20-300 nM) toward the recombinant mouse, rat, and human sEH. Quantitative analysis of commercial maca products revealed that certain products contain known macamides (1-5, 8-12) at therapeutically relevant total concentrations (≥3.29 mg/g of root), while the inhibitory potency of L. meyenii extracts directly correlates with the sum of concentration/IC50 ratios of macamides present. Considering both its in vitro efficacy and high abundance in commercial products, N-benzyl-linoleamide (4) was identified as a particularly relevant macamide that can be utilized for in vivo studies. Following oral administration in the rat, compound 4 not only displayed acceptable pharmacokinetic characteristics but effectively reduced lipopolysaccharide-induced inflammatory pain. Inhibition of sEH by macamides provides a plausible biological mechanism of action to account for several beneficial effects previously observed with L. meyenii treatments.